Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CIPLA

Amneal Launches Its Generic Lanreotide Immediately While the Brand Still Posts Nearly a Billion in US Sales

FDA cleared Amneal's generic lanreotide, and it launched immediately. Why more competition has not yet cut what patients pay for monthly injections.

Medical Daily

Stocks in news: Groww, Tata Motors PV, Cipla, Varun Beverages and Axis Bank

The Indian equity market experienced a positive turnaround on Tuesday, August 25, highlighted by the Nifty 50 making a robust recovery. Anticipation builds for Wednesday as Groww gears up for a significant block deal, while Cipla faces new USFDA inspectional observations. In other news, Tata Motors Passenger Vehicles is set…

The Economic Times

Pharma giant Cipla completes merger with wholly-owned subsidiary Inzpera Health Sciences

Pharmaceuticals giant Cipla announced its merger with Inzpera Healthsciences Limited on Wednesday. This consolidation aims for more efficient resource utilisation and greater economies of scale. The merger will improve operating parameters and maximise shareholder value through integration. Greater efficiency in cash management and access to cash flows is also expected.…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks in news: PB Fintech, LIC, Trent, Ola Electric, and Cipla

In a day of mixed economic signals, Indian markets displayed notable volatility before settling at a flat close. PB Fintech enjoyed a substantial rise in profits thanks to robust growth in insurance premiums. ONGC is also gearing up to ink deals with Venezuela for managing oil blocks. Simultaneously, Ola Electric…

The Economic Times

Nifty Q1 earnings grow 11% to beat estimate, says Motilal Oswal; picks Bharti Airtel, SBI, ICICI Bank among top bets

Nifty companies have posted a stronger-than-expected start to Q1 earnings, with profits of 39 reporting constituents rising 11% YoY, beating Motilal Oswal’s 7% estimate. Reliance Industries, JSW Steel, ICICI Bank, Bajaj Finance and Axis Bank drove 59% of incremental earnings growth, while InterGlobe Aviation, ITC, Dr Reddy’s, Cipla and Maruti…

The Economic Times

Stocks in news: Infosys, Cipla, Meesho, Suzlon Energy, IndiGo, NTPC

Markets extended their losing streak for a fourth consecutive session. Infosys reported a 12% year-on-year profit growth in its first quarter. Cipla's net profit fell 39% due to weakness in its North America business. IndiGo reported a loss of Rs 238 crore in its first quarter. Several other companies will…

The Economic Times

Cipla Q1 Results: Cons profit drops 39% YoY to Rs 789 crore; revenue rises marginally

Cipla Q1 Results: Pharma major Cipla reported a 39% year-on-year decline in Q1FY27 consolidated net profit to Rs 789 crore, mainly due to a high base, while revenue from operations rose a modest 2.3% to Rs 7,119 crore. The company's EBITDA also declined, with margins contracting sharply compared with the…

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Stocks in news: Infosys, IndusInd Bank, Eternal, Adani Green, Dr Reddy's

Indian markets experienced a decline on Wednesday due to global and geopolitical concerns. IndusInd Bank reported a significant profit increase while Eternal saw substantial net profit growth. BPCL, however, posted a considerable loss in the first quarter. Adani Green announced a moderate profit rise, and Dr Reddy's profit declined. Several…

The Economic Times

Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investors

Donald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analysts believe the long-term impact could be limited, citing India's manufacturing cost advantage, US-based production facilities of several drugmakers and uncertainty over how and when the tariffs will be implemented.

The Economic Times

Indian pharma firms may yet survive Trump's 200% tariff bombshell

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited. India's cost advantage, America's dependence on imported generics and lengthy US factory approval timelines could make large-scale manufacturing shifts difficult despite Trump's…

The Economic Times

200% Trump tariff shock? India’s cheap pills may still beat US rivals

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage may help many drugs remain competitive in the US market, according to the Global Trade Research Initiative (GTRI).

The Economic Times

Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufacturing and supply chain strategies. After this period, tariffs will escalate significantly, impacting export economics. Several Indian firms already have US manufacturing operations for flexibility. The next two years will shape how…

The Economic Times

Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028

Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff plan on imported generic drugs. While generics will remain tariff-free for two years, duties will rise to 100% from August 2028 and 200% from August 2029, weighing…

The Economic Times

Airtel to Trent: 44 cos likely to report double-digit profit slump in Q1. Are your stocks on the list?

Motilal Oswal expects 44 companies, including Bharti Airtel, Trent, IndiGo, HAL, GAIL and Cipla, to report double-digit year-on-year profit declines in the June quarter. Higher energy costs, weaker demand, geopolitical tensions and margin pressure are expected to weigh on earnings, even as overall corporate profit growth slows in Q1.

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?

Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla's performance remains strong, supported by its respiratory portfolio. Citi sees earnings bottoming out and highlights attractive…

The Economic Times

Cipla appoints health chief Shivam Puri to lead One India business

Cipla has appointed Shivam Puri as the new Chief Executive Officer for its One India Business. This significant leadership change will take effect from July 1. Puri currently heads Cipla Health, a role he has held since 2019. His extensive experience in consumer goods and healthcare will now steer Cipla's…

MarketBeat

Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter

Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. Ram Selvaraju, managing dir

The Economic Times

Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked target

Cipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despite a weak Q4 performance. The stock hit an intraday high of Rs 1,432.10 as investors focused on future growth prospects over near-term earnings pressure.

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividend

Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This contrasts with Rs 1,222 crore reported in the same period last year. The company's Board has recommended a final dividend of Rs 13 per share for the fiscal…

The Economic Times

Stocks in news: Airtel, Tata Motors, Dr Reddy's, NTPC, Dixon Technologies

Markets faced selling pressure on Tuesday due to weak global cues and macroeconomic concerns, with the Nifty approaching support at 23,150. Several companies like Airtel, Tata Motors, and Dr Reddy's are in focus due to earnings reports and other news developments.

Times Life

7 Things That Will Get Cheaper After Budget 2026

Most budgets promise relief. Very few actually change what you pay in real life. Budget 2026 is one of those rare ones that works quietly. There were no dramatic tax cuts, no loud announcements, and no instant price drops flashed across screens. Yet, beneath the fine print, the government made…

StockNews.com

3 High-Growth Biotech Stocks to Watch

Amid the growing innovations, emphasis on enhanced treatment alternatives, and rapid AI adoption, the biotechnology industry is poised for solid long-term growth. Thus, investors could consider adding high-growth biotech stocks MannKind (MNKD), Amicus Therapeutics (FOLD), and Esperion Therapeutics (ESPR) to their watchlist. Continue reading.

StockNews.com

3 Biotech Stocks to Buy Before Their Earnings Announcements

Buoyed by encouraging clinical trial results and new advancements, the biotech industry is on a strong upward trajectory. Given the sector’s growing potential, I have highlighted three biotech stocks, Exelixis (EXEL), Gilead Sciences (GILD), and Halozyme Therapeutics (HALO), to consider before their second-quarter earnings report. Read on….

Newslaundry

‘My posts are backed up with solid evidence, research’: Liver Doc on Himalaya Wellness suit

“Based on strong scientific evidence, or because of lack of it, I have been critical of several of Himalaya Wellness’ products,” said doctor-influencer Cyriac Abby Philips aka The Liver Doc, whose X account was suspended today for posting “defamatory remarks” against the ayurvedic pharma company.

The Independent UK

Revealed: Hundreds of millions in UK taxpayers’ money handed to companies still operating in Russia

Exclusive: British government accused of indirectly helping to fund Putin’s war with £294m contracts

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.